BARICITINIB
Manufacturer: Eli Lilly and Company
Score: 144.0
Olumiant (Baricitinib) is a Janus kinase (JAK) inhibitor used to treat adult patients with moderately to severely active rheumatoid arthritis, COVID-19 in hospitalized adults, and severe alopecia areata. Key clinical findings indicate its efficacy in these conditions, but it also carries important safety information, including warnings about serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The drug has specific dosing recommendations, including initial dosing and potential adjustments based on patient conditions. Special population considerations, such as use during pregnancy, in nursing mothers, pediatric use, and geriatric use, are also crucial for safe administration.
Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB)
Dosage modifications are recommended for patients with renal or hepatic impairment, and for those taking strong OAT3 inhibitors
2 mg once daily
Not established
4 mg once daily for up to 14 days
Not established
2 mg once daily, may increase to 4 mg once daily if response is not adequate
Not established